Accounts Receivable, after Allowance for Credit Loss, Current of Pharma-Bio Serv, Inc. from 31 Oct 2010 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Pharma-Bio Serv, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Oct 2010 to 31 Oct 2025.
  • Pharma-Bio Serv, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Oct 2025 was $2,360,682, a 6% decline year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Pharma-Bio Serv, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,360,682 -$150,227 -6% 31 Oct 2025 10-K 29 Jan 2026 2025 FY
Q2 2025 $2,015,529 -$583,630 -22% 31 Jul 2025 10-Q 15 Sep 2025 2025 Q3
Q1 2025 $2,684,052 +$69,235 +2.6% 30 Apr 2025 10-Q 16 Jun 2025 2025 Q2
Q4 2024 $2,681,752 +$274,172 +11% 31 Jan 2025 10-Q 17 Mar 2025 2025 Q1
Q3 2024 $2,510,909 -$1,429,936 -36% 31 Oct 2024 10-K 29 Jan 2026 2025 FY
Q2 2024 $2,599,159 -$2,031,948 -44% 31 Jul 2024 10-Q 16 Sep 2024 2024 Q3
Q1 2024 $2,614,817 -$2,414,238 -48% 30 Apr 2024 10-Q 14 Jun 2024 2024 Q2
Q4 2023 $2,407,580 -$1,918,192 -44% 31 Jan 2024 10-Q 18 Mar 2024 2024 Q1
Q3 2023 $3,940,845 -$1,041,655 -21% 31 Oct 2023 10-K 29 Jan 2025 2024 FY
Q2 2023 $4,631,107 -$171,649 -3.6% 31 Jul 2023 10-Q 14 Sep 2023 2023 Q3
Q1 2023 $5,029,055 -$449,157 -8.2% 30 Apr 2023 10-Q 14 Jun 2023 2023 Q2
Q4 2022 $4,325,772 -$720,709 -14% 31 Jan 2023 10-Q 17 Mar 2023 2023 Q1
Q3 2022 $4,982,500 +$369,358 +8% 31 Oct 2022 10-K 29 Jan 2024 2023 FY
Q2 2022 $4,802,756 -$5,279,466 -52% 31 Jul 2022 10-Q 14 Sep 2022 2022 Q3
Q1 2022 $5,478,212 -$4,886,463 -47% 30 Apr 2022 10-Q 14 Jun 2022 2022 Q2
Q4 2021 $5,046,481 -$4,518,844 -47% 31 Jan 2022 10-Q 17 Mar 2022 2022 Q1
Q3 2021 $4,613,142 -$5,114,449 -53% 31 Oct 2021 10-K 30 Jan 2023 2022 FY
Q2 2021 $10,082,222 +$37,860 +0.38% 31 Jul 2021 10-Q 14 Sep 2021 2021 Q3
Q1 2021 $10,364,675 +$387,694 +3.9% 30 Apr 2021 10-Q 14 Jun 2021 2021 Q2
Q4 2020 $9,565,325 +$1,848,752 +24% 31 Jan 2021 10-Q 17 Mar 2021 2021 Q1
Q3 2020 $9,727,591 +$946,565 +11% 31 Oct 2020 10-K 11 Feb 2022 2021 FY
Q2 2020 $10,044,362 +$2,241,915 +29% 31 Jul 2020 10-Q 14 Sep 2020 2020 Q3
Q1 2020 $9,976,981 +$3,313,557 +50% 30 Apr 2020 10-Q 15 Jun 2020 2020 Q2
Q4 2019 $7,716,573 +$2,260,290 +41% 31 Jan 2020 10-Q 16 Mar 2020 2020 Q1
Q3 2019 $8,781,026 +$3,587,641 +69% 31 Oct 2019 10-K 01 Feb 2021 2020 FY
Q2 2019 $7,802,447 +$2,622,868 +51% 31 Jul 2019 10-Q 16 Sep 2019 2019 Q3
Q1 2019 $6,663,424 +$95,971 +1.5% 30 Apr 2019 10-Q 14 Jun 2019 2019 Q2
Q4 2018 $5,456,283 -$596,798 -9.9% 31 Jan 2019 10-Q 18 Mar 2019 2019 Q1
Q3 2018 $5,193,385 -$1,124,005 -18% 31 Oct 2018 10-K 29 Jan 2020 2019 FY
Q2 2018 $5,179,579 -$1,766,916 -25% 31 Jul 2018 10-Q 14 Sep 2018 2018 Q3
Q1 2018 $6,567,453 -$44,347 -0.67% 30 Apr 2018 10-Q 14 Jun 2018 2018 Q2
Q4 2017 $6,053,081 +$38,070 +0.63% 31 Jan 2018 10-Q 19 Mar 2018 2018 Q1
Q3 2017 $6,317,390 -$535,733 -7.8% 31 Oct 2017 10-K 29 Jan 2019 2018 FY
Q2 2017 $6,946,495 -$430,955 -5.8% 31 Jul 2017 10-Q 14 Sep 2017 2017 Q3
Q1 2017 $6,611,800 -$1,093,186 -14% 30 Apr 2017 10-Q 14 Jun 2017 2017 Q2
Q4 2016 $6,015,011 -$1,347,150 -18% 31 Jan 2017 10-Q 17 Mar 2017 2017 Q1
Q3 2016 $6,853,123 -$594,861 -8% 31 Oct 2016 10-K 29 Jan 2018 2017 FY
Q2 2016 $7,377,450 -$303,044 -3.9% 31 Jul 2016 10-Q 14 Sep 2016 2016 Q3
Q1 2016 $7,704,986 +$597,065 +8.4% 30 Apr 2016 10-Q 14 Jun 2016 2016 Q2
Q4 2015 $7,362,161 +$1,076,318 +17% 31 Jan 2016 10-Q 16 Mar 2016 2016 Q1
Q3 2015 $7,447,984 +$1,062,409 +17% 31 Oct 2015 10-K 31 Jan 2017 2016 FY
Q2 2015 $7,680,494 +$1,294,475 +20% 31 Jul 2015 10-Q 14 Sep 2015 2015 Q3
Q1 2015 $7,107,921 +$68,651 +0.98% 30 Apr 2015 10-Q 15 Jun 2015 2015 Q2
Q4 2014 $6,285,843 +$614,448 +11% 31 Jan 2015 10-Q 17 Mar 2015 2015 Q1
Q3 2014 $6,385,575 -$1,018,412 -14% 31 Oct 2014 10-K 29 Jan 2016 2015 FY
Q2 2014 $6,386,019 -$1,665,848 -21% 31 Jul 2014 10-Q 15 Sep 2014 2014 Q3
Q1 2014 $7,039,270 -$572,618 -7.5% 30 Apr 2014 10-Q 16 Jun 2014 2014 Q2
Q4 2013 $5,671,395 -$2,048,228 -27% 31 Jan 2014 10-Q 17 Mar 2014 2014 Q1
Q3 2013 $7,403,987 -$176,180 -2.3% 31 Oct 2013 10-K 29 Jan 2015 2014 FY
Q2 2013 $8,051,867 +$866,252 +12% 31 Jul 2013 10-Q 16 Sep 2013 2013 Q3
Q1 2013 $7,611,888 +$667,080 +9.6% 30 Apr 2013 10-Q 14 Jun 2013 2013 Q2
Q4 2012 $7,719,623 +$1,972,678 +34% 31 Jan 2013 10-Q 18 Mar 2013 2013 Q1
Q3 2012 $7,580,167 +$2,715,551 +56% 31 Oct 2012 10-K 29 Jan 2014 2013 FY
Q2 2012 $7,185,615 +$3,067,968 +75% 31 Jul 2012 10-Q 14 Sep 2012 2012 Q3
Q1 2012 $6,944,808 30 Apr 2012 10-Q 14 Jun 2012 2012 Q2
Q4 2011 $5,746,945 31 Jan 2012 10-Q 16 Mar 2012 2012 Q1
Q3 2011 $4,864,616 +$2,344,209 +93% 31 Oct 2011 10-K 29 Jan 2013 2012 FY
Q2 2011 $4,117,647 31 Jul 2011 10-Q 14 Sep 2011 2011 Q3
Q3 2010 $2,520,407 31 Oct 2010 10-K/A 31 Jan 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.